Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.32 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21366311 | 0.88 | KMT2A (0.39) | KMT2AMEN1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL26298535 | 0.84 | SMN1; SMN2 (0.35) | KDM4EHTTSMN1; SMN2HSD17B3NOTUM | |
| SCHEMBL19604359 | 0.83 | KMT2A (0.39) | KMT2AMEN1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL23961790 | 0.83 | LMNA (0.35) | KDM4EHTTSMN1; SMN2HSD17B3NOTUM | |
| SCHEMBL25011607 | 0.82 | RIPK1 (0.34) | KMT2AMEN1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL24252205 | 0.82 | LMNA (0.31) | KDM4E | |
| SCHEMBL18179935 | 0.81 | KMT2A (0.40) | KMT2AMEN1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL24252206 | 0.81 | — | — | |
| SCHEMBL21366027 | 0.81 | KMT2A (0.36) | KMT2AMEN1KDM4EHTTSMN1; SMN2 | |
| SCHEMBL14296207 | 0.80 | KMT2A (0.39) | KMT2AMEN1KDM4EHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2021-04-15 | — | — | US | disclosed |
| US-10603386-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170348424-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | KMT2A 2203/4885MEN1 4707/4885KDM4E 2904/4885 |
| US-20210106690-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, CLTB, BRAP | KMT2A 1709/4885MEN1 4632/4885KDM4E 2476/4885 |
| US-10603386-B2 | Protein-polymer-drug conjugates | PBRM1, CLTB, BRAP | KMT2A 1784/4885MEN1 4621/4885KDM4E 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.